Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022     AMGEN INC. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-37702   95-3540776 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive Thousand Oaks , California     91320-1799 (Address of Principal Executive Offices)     (Zip Code) (805) 447-1000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   AMGN   The NASDAQ Stock Market LLC 2.000% Senior Notes Due 2026   AMGN26   The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on May 17, 2022. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows: Item 1 - Election of Directors Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2023 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.   Name    Votes For         Votes Against         Abstain         Broker Non- Votes Dr. Wanda M. Austin    393,262,568     6,448,766     738,582     63,585,494 Mr. Robert A. Bradway    375,943,441     21,463,442     3,043,033     63,585,494 Dr. Brian J. Druker    392,906,914     6,807,605     735,397     63,585,494 Mr. Robert A. Eckert    336,327,670     62,799,670     1,322,576     63,585,494 Mr. Greg C. Garland    364,253,481     34,483,152     1,713,283     63,585,494 Mr. Charles M. Holley, Jr.    381,334,073     17,752,766     1,363,077     63,585,494 Dr. S. Omar Ishrak    366,717,639     32,920,612     811,665     63,585,494 Dr. Tyler Jacks    392,012,356     7,712,005     725,555     63,585,494 Ms. Ellen J. Kullman    388,527,454     10,667,223     1,255,239     63,585,494 Ms. Amy E. Miles    386,328,380     12,833,592     1,287,944     63,585,494 Dr. Ronald D. Sugar    332,321,569     66,949,303     1,179,044     63,585,494 Dr. R. Sanders Williams    387,372,234     11,822,332     1,255,350     63,585,494 Item 2 - Advisory Vote to Approve Our Executive Compensation The advisory vote to approve our executive compensation was approved.   For:    357,838,927 Against:    40,742,450 Abstain:    1,868,539 Broker Non-Votes:    63,585,494 Item 3 - Ratification of Selection of Independent Registered Public Accountants Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2022. No Broker Non-Votes resulted from the vote on this proposal.   For:    436,530,705 Against:    26,765,473 Abstain:    739,232 No other matters were submitted for stockholder action. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       AMGEN INC. Date: May 18, 2022     By:                 /s/ Jonathan P. Graham     Name:   Jonathan P. Graham     Title:   Executive Vice President, General Counsel and Secretary